bosutinib — United Healthcare
myeloid/lymphoid neoplasms with eosinophilia and ABL1 rearrangement
Initial criteria
- Diagnosis of myeloid/lymphoid neoplasms with eosinophilia
- Presence of ABL1 rearrangement
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Bosulif therapy
Approval duration
12 months